Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/109426
dc.contributor.author | Wedzicha, Jadwiga A. |
---|---|
dc.contributor.author | Agustí García-Navarro, Àlvar |
dc.contributor.author | Donaldson, Gavin |
dc.contributor.author | Chuecos, Ferran |
dc.contributor.author | Lamarca, Rosa |
dc.contributor.author | Garcia Gil, Esther |
dc.date | 2017-04-05T15:06:05Z |
dc.date | 2017-04-05T15:06:05Z |
dc.date | 2016-05-09 |
dc.date | 2017-04-05T15:06:05Z |
dc.identifier | 1176-9106 |
dc.identifier | 668953 |
dc.identifier | 27159613 |
dc.identifier.uri | http://hdl.handle.net/2445/109426 |
dc.description | We investigated the effect of the long-acting muscarinic antagonist aclidinium bromide on chronic obstructive pulmonary disease (COPD) exacerbations by pooling data from five randomized, placebo-controlled,parallel-group Phase III studies of 3-6 months' duration. Data were pooled from the aclidinium 400 μg twice-daily (BID) and placebo arms (N = 2,521) and stratified by Global initiative for chronic Obstructive Lung Disease (GOLD) group (A, B, C and D). Results showed that fewer patients experienced 1 exacerbation with aclidinium (any severity: 12.5%; moderate to severe: 10.9%) compared with placebo (any severity: 15.7%; moderate to severe: 13.3%) and the odds of experiencing 1 exacerbation of any severity were reduced in patients receiving aclidinium (odds ratio = 0.78, p = 0.039). Furthermore, aclidinium reduced the rate of exacerbations compared with placebo (any severity: rate ratio = 0.79, p = 0.026; moderate to severe: 0.80, p = 0.044). The time to first exacerbation of any severity was delayed with aclidinium compared with placebo (hazard ratio = 0.79, p = 0.026) and there was a numerical delay in time to first moderate-to-severe exacerbation. Finally, the effects of aclidinium on exacerbations versus placebo were greater in patients in GOLD Groups B and D; however, it is of note that only 10.7% of patients were classified in Group A or C. In summary, the results indicate that aclidinium 400 μg BID reduces the frequency of COPD exacerbations compared with placebo and that these effects are greater in symptomatic patients. |
dc.format | 9 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Dove Medical Press |
dc.relation | Reproducció del document publicat a: https://doi.org/10.3109/15412555.2016.1170111 |
dc.relation | International Journal of Chronic Obstructive Pulmonary Disease, 2016, vol. 13, num. 6, p. 669-676 |
dc.relation | https://doi.org/10.3109/15412555.2016.1170111 |
dc.rights | cc-by-nc (c) Wedzicha et al., 2016 |
dc.rights | http://creativecommons.org/licenses/by-nc/3.0/es |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Malalties pulmonars obstructives cròniques |
dc.subject | Malalties dels pulmons |
dc.subject | Chronic obstructive pulmonary diseases |
dc.subject | Pulmonary diseases |
dc.title | Effect of aclidinium bromide on exacerbations in patients with moderate to severe COPD: a pooled analysis of five Phase III, randomized, placebo-controlled studies |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |